ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) was the target of a significant decline in short interest in December. As of December 31, there was short interest totaling 94,400 shares, a decrease of 46.1% from the total of 175,100 shares as of December 15. Currently, 0.2% of the company’s shares are sold short. Based on an average daily trading volume of 433,900 shares, the day-to-cover ratio is currently 0.2 days.

ASLN has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating on shares of ASLAN Pharmaceuticals in a research report on Tuesday, December 7. BTIG Research reissued a “hold” rating on ASLAN Pharmaceuticals shares in a research report on Tuesday, October 5. Finally, Zacks Investment Research downgraded ASLAN Pharmaceuticals from a “buy” rating to a “hold” rating in a Monday, Nov. 1, research report.

A number of institutional investors have recently changed their positions in the company. Tang Capital Management LLC bought a new position in ASLAN Pharmaceuticals in Q3 worth $1,736,000. Millennium Management LLC increased its equity stake in ASLAN Pharmaceuticals by 8.8% in the third quarter. Millennium Management LLC now owns 1,468,207 shares of the company worth $2,613,000 after purchasing an additional 118,919 shares during the period. Point72 Asset Management LP bought a new stake in ASLAN Pharmaceuticals stock in Q3 worth $445,000. Morgan Stanley increased its stake in shares of ASLAN Pharmaceuticals by 3.5% in the 3rd quarter. Morgan Stanley now owns 239,508 shares of the company worth $426,000 after purchasing an additional 8,049 shares during the period. Finally, Affinity Asset Advisors LLC purchased a new stake in shares of ASLAN Pharmaceuticals in Q3 at a value of $445,000. 66.31% of the shares are currently held by institutional investors.

Shares of NASDAQ: ASLN opened at $1.08 on Friday. The company has a market capitalization of $41.03 million, a PE ratio of -2.25 and a beta of 2.34. The company has a fifty-day moving average price of $1.34 and a 200-day moving average price of $2.11. ASLAN Pharmaceuticals has a 1-year low of $1.02 and a 1-year high of $6.75.

ASLAN Pharmaceuticals (NASDAQ:ASLN) last reported quarterly earnings data on Monday, October 25. The company reported ($0.12) EPS for the quarter, beating Thomson Reuters consensus estimate of ($0.13) by $0.01. On average, analysts expect ASLAN Pharmaceuticals to post -0.47 EPS for the current year.

About ASLAN Pharmaceuticals

Aslan Pharmaceuticals Ltd. is a clinical-stage oncology-focused biopharmaceutical company engaged in the development of novel therapies. It focuses on atopic dermatitis, other immunological indications and autoimmune diseases. Its pipeline includes varlitinib, ASLAN003, ASLAN004 and AhR Antagonist.

Feature story: What is the performance rating of the market?

This instant news alert was powered by MarketBeat’s narrative science technology and financial data to provide readers with the fastest and most accurate reports. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send questions or comments about this story to [email protected]

Should you invest $1,000 in ASLAN Pharmaceuticals right now?

Before you consider ASLAN Pharmaceuticals, you’ll want to hear this.

MarketBeat tracks daily the highest rated and most successful research analysts on Wall Street and the stocks they recommend to their clients. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the market takes off…and ASLAN Pharmaceuticals was not on the list.

While ASLAN Pharmaceuticals currently has a “Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.

See the 5 actions here